{"id":"coadministered-artesunate-plus-amodiaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL361497","moleculeType":"Small molecule","molecularWeight":"384.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate, a semi-synthetic artemisinin derivative, is activated by parasite heme to form reactive intermediates that alkylate parasite proteins and disrupt mitochondrial function. Amodiaquine, a 4-aminoquinoline, inhibits the parasite's ability to detoxify heme, leading to accumulation of toxic heme byproducts. The combination provides enhanced and rapid parasite clearance with reduced risk of resistance development compared to monotherapy.","oneSentence":"Artesunate and amodiaquine work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while amodiaquine inhibits parasite heme detoxification.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:15.657Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by Plasmodium vivax, ovale, and malariae"}]},"trialDetails":[{"nctId":"NCT03764527","phase":"PHASE4","title":"Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2002-11-01","conditions":"Plasmodium Falciparum Malaria","enrollment":408}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Coadministered Artesunate plus Amodiaquine","genericName":"Coadministered Artesunate plus Amodiaquine","companyName":"Professor Anders Björkman","companyId":"professor-anders-bj-rkman","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate and amodiaquine work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while amodiaquine inhibits parasite heme detoxification. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}